<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04996706</url>
  </required_header>
  <id_info>
    <org_study_id>21-001804</org_study_id>
    <secondary_id>U01CA195568-06A1</secondary_id>
    <nct_id>NCT04996706</nct_id>
  </id_info>
  <brief_title>Lymphoma Epidemiology of Outcomes Cohort Years 6-10</brief_title>
  <acronym>LEO</acronym>
  <official_title>Lymphoma Epidemiology of Outcomes Cohort Years 6-10</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this infrastructure protocol is to build and maintain a large and diverse&#xD;
      observational cohort study to support broad and cutting-edge research focused on NHL&#xD;
      prognosis and survivorship. The LEO cohort will promote identification of clinical (including&#xD;
      co-morbid diseases), epidemiologic (including lifestyle and other exposures), host genetic,&#xD;
      tumor, and treatment factors that impact multiple outcomes (including event-free, overall and&#xD;
      lymphoma-specific survival; new onset comorbidities; and patient-reported outcomes). This&#xD;
      resource also will allow examination of the interaction among these factors in order to&#xD;
      better understand the clinical and molecular epidemiology of outcomes in NHL. Ultimately,&#xD;
      this approach will drive discovery and validation of treatment endpoints, improve&#xD;
      prognostication, and identify novel approaches to improve short and long-term outcomes for&#xD;
      NHL patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To extend recruitment at all 8 LEO centers as part of LEO2.0 using a single IRB, with a&#xD;
           goal of recruiting an additional 8,000 newly diagnosed NHL patients (with funding from&#xD;
           the NIH renewal grant to enroll 3,400) focused on Hispanic (N=900), African Americans&#xD;
           (N=580), and Asian (N=200) participants (doubling the current sample size for these&#xD;
           groups; adolescent and young adult patients age 18-39 years (N=870; 87% increase); and&#xD;
           non-metro and rural patients of all ages and race/ethnicities (N=1,208, 72% increase)&#xD;
           for a total cohort of over 21,000 patients;&#xD;
&#xD;
        2. To review pathology at diagnosis and relapse of all LEO cases and maintain a central&#xD;
           tumor bank for selected NHL subtypes that includes an H&amp;E slide, formalin-fixed,&#xD;
           paraffin-embedded (FFPE) tissue samples in a tissue microarray (TMA), and extracted&#xD;
           tumor DNA and RNA;&#xD;
&#xD;
        3. To collect a peripheral blood sample and maintain a central biorepository of DNA, serum,&#xD;
           plasma, and buffy coat;&#xD;
&#xD;
        4. To continue to prospectively follow all participants in the LEO cohort to ascertain&#xD;
           disease progression/relapse, retreatment, transformation, second cancers, survival&#xD;
           (including cause of death), updated exposures, patient-reported outcomes (PROs), and&#xD;
           other long-term health outcomes;&#xD;
&#xD;
        5. To annotate and harmonize all cases with clinical, epidemiologic, pathology and&#xD;
           treatment data, including development of new informatics enhancements to capture&#xD;
           clinical data from electronic health records (EHRs), digital pathology, and radiology&#xD;
           images, geocoded data from residence at diagnosis with linkage to public databases to&#xD;
           enhance data on environmental exposures and socioeconomic factors; and&#xD;
&#xD;
        6. Facilitate research projects that use this infrastructure, promote interactions with&#xD;
           NCI-supported clinical trials networks, patient advocacy groups, and other&#xD;
           collaborators, and to make the LEO resource accessible to patients and providers with&#xD;
           publicly available risk calculators based on LEO data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Time Frame: Short (&lt;5 years), medium (5-10 years), and long-term (&gt;10 years)</time_frame>
    <description>Time from date of diagnosis to date of death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>Time Frame: Short (&lt;5 years), medium (5-10 years), and long-term (&gt;10 years)</time_frame>
    <description>Time from date of diagnosis to date of first defined event (disease progression, relapse or re-treatment for lymphoma, or death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphoma Specific Survival (LSS)</measure>
    <time_frame>Time Frame: Short (&lt;5 years), medium (5-10 years), and long-term (&gt;10 years)</time_frame>
    <description>Time from date of diagnosis to date of death due to lymphoma</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1. Blood Collection&#xD;
&#xD;
        2. DNA - Blood&#xD;
&#xD;
        3. Tumor DNA and RNA Extraction&#xD;
&#xD;
        4. Formalin Fixed Paraffin Embedded Tissue (FFPE) H&amp;E Slide&#xD;
&#xD;
        5. Tissue Microarrays (TMA)&#xD;
&#xD;
        6. Clinical Residual&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Newly diagnosed non-Hodgkin Lymphoma willing to provide a research blood sample, return&#xD;
        enrollment and follow-up questionnaires, and allow access to medical records.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed non-Hodgkin Lymphoma (NHL), within 183 days of enrollment&#xD;
&#xD;
          -  Patients may have been treated as long as initial NHL diagnosis is within 6 months of&#xD;
             enrollment&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Lymphoma diagnosis greater than 184 days from date of consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>James Cerhan, M.D.,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami: Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>â€¢ Washington School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>James Cerhan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lymphatic Diseases</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Lymphoproliferative Disorders</keyword>
  <keyword>Immunoproliferative Disorders</keyword>
  <keyword>Immune System Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Sharing of data can be requested through the LEO Cohort website.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Will become available upon publication</ipd_time_frame>
    <ipd_access_criteria>Data sharing can occur only after going through group approvals.</ipd_access_criteria>
    <ipd_url>https://leocohort.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

